Streetbeat News

Earnings

GWAV

LICY

SMR

ZCAR

In Tuesday's pre-market session, several industrials stocks showed significant movement. Zoomcar Holdings (ZCAR) led the gainers with a 50% increase, while Greenwave Tech Solns (GWAV) experienced the largest drop among the losers, declining by 52.6%. Notably, companies like Li-Cycle Holdings (LICY), Spire Global (SPIR), and Bridger Aerospace Gr (BAER) reported upward movements following their recent earnings reports. Conversely, NuScale Power (SMR) saw a decline after its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 1:05 pm

GVP

PRSO

SMCI

In Tuesday's pre-market session, several information technology stocks showed significant movement. GSE Systems, MultiSensor AI Holdings, Verb Tech, One Stop Systems, MariaDB, and Quantum were among the gainers, with increases ranging from 6.25% to 13.0%. On the losing side, Peraso, Red Cat Holdings, Airship AI Holdings, Super Micro Computer, MicroStrategy, and Comtech Telecom saw declines between 9.14% and 17.5%, with some attributing their drops to recent earnings reports.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 1:05 pm

CERS

Cerus Corporation's stock price increased following the announcement that its ReCePI Phase 3 trial of the INTERCEPT Blood System met its primary efficacy endpoint.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 1:05 pm

MRSN

Mersana Therapeutics (NASDAQ:MRSN) has received mixed analyst ratings over the past three months, with a shift towards a more positive outlook. The average 12-month price target has increased by 65% to $6.6. Analysts from JP Morgan, Wedbush, Truist Securities, Baird, and Guggenheim have provided updates, with actions ranging from 'Announces' to 'Raises'. The company's financials show a decline in revenue growth and challenges in ROE, but strong net margin and ROA. Mersana is a clinical-stage biopharmaceutical company with several early and preclinical stage programs.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 1:00 pm

CERS

CRNX

HOTH

Cerus Corporation (CERS) announced its ReCePI Phase 3 trial of INTERCEPT Blood System met its primary efficacy endpoint, with no significant difference in safety endpoints. Crinetics Pharmaceuticals (CRNX) shares rose after its Phase 3 trial of paltusotine in acromegaly met primary and all secondary endpoints. Hoth Therapeutics (HOTH) reported HT-ALZ as a promising solution for Alzheimer's disease-related neuroinflammation and cognitive deficits.

Portfolio Pulse from ryanfaloona@benzinga.com

March 19, 2024 | 12:41 pm

BNRG

Brenmiller Energy reported its FY23 financial results, revealing a decrease in cash and cash equivalents to $3.18M from $6.51M in the previous year. The decrease was due to net cash used in operating activities and funds spent on the Dimona production facility, despite raising approximately $6.3M in net proceeds from fundraising. In January 2024, Brenmiller raised an additional $4M in gross proceeds through an SEC-registered offering.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 12:39 pm

ZEO

Zeo Energy Corp. reported its Q4 2023 financial results, showing a slight revenue increase to $23.4M from $22.9M YoY but a shift to a net loss of $0.1M from a net income of $1.1M YoY. The full year results also saw revenue growth to $110.1M, up 23.7% YoY, though net income fell to $6.2M from $8.7M. The decrease in net income for both periods was attributed to costs related to new technology launches, legal and consulting expenses, and one-time costs associated with a Business Combination.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 12:35 pm

ICCM

IceCure Medical announced positive topline results from its ICE3 cryoablation breast cancer study, with 96.39% of patients showing no local recurrence. The company plans to submit the full dataset to the FDA in April for marketing authorization of ProSense® for early-stage breast cancer treatment. This study is the largest of its kind in the U.S. for early-stage low-risk malignant breast tumors, with no significant device-related adverse events reported.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 12:34 pm

SPY

February's housing starts exceeded expectations, coming in at 1.521 million compared to the estimated 1.43 million. This indicates a stronger than anticipated construction sector.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 12:30 pm

ARQ

FCX

SCCO

USLM

As of March 19, 2024, four materials sector stocks are considered overbought based on their RSI values, suggesting potential short-term performance concerns. United States Lime & Minerals, Inc. (USLM), Arq, Inc. (ARQ), Freeport-McMoRan Inc. (FCX), and Southern Copper Corporation (SCCO) have shown significant price movements and are highlighted for their momentum, which may indicate a need for caution among momentum investors.

Portfolio Pulse from Avi Kapoor

March 19, 2024 | 12:28 pm